[breadcrumb_custom]

Buy, Sell Or Hold Kymera Therapeutics Inc (NASDAQ:KYMR) At $37.21?

In last trading session, Kymera Therapeutics Inc (NASDAQ:KYMR) saw 0.74 million shares changing hands with its beta currently measuring 2.22. Company’s recent per share price level of $37.21 trading at $3.23 or 9.51% at ring of the bell on the day assigns it a market valuation of $2.21B. That closing price of KYMR’s stock is at a premium of 4.73% from its 52-week high price of $35.45 and is indicating a premium of 74.2% from its 52-week low price of $9.60. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.66 million shares which gives us an average trading volume of 926.87K if we extend that period to 3-months.

Kymera Therapeutics Inc (NASDAQ:KYMR) trade information

Upright in the green during last session for gaining 9.51%, in the last five days KYMR remained trading in the green while hitting it’s week-highest on Friday, 02/09/24 when the stock touched $37.21 price level, adding 0.13% to its value on the day. Kymera Therapeutics Inc’s shares saw a change of 46.15% in year-to-date performance and have moved 12.86% in past 5-day. Kymera Therapeutics Inc (NASDAQ:KYMR) showed a performance of 27.83% in past 30-days. Number of shares sold short was 8.62 million shares which calculate 7.11 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Kymera Therapeutics Inc (KYMR) estimates and forecasts

Statistics highlight that Kymera Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 84.12% of value to its shares in past 6 months, showing an annual growth rate of 7.32% while that of industry is 15.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -56.21% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 10.60% while estimates for its earnings growth in next 5 years are of 1.90%.

KYMR Dividends

Kymera Therapeutics Inc is more likely to be releasing its next quarterly report between February 21 and February 26 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

On Key

Related Posts